Tyco, CR Bard to merge; deal terminated

Tyco International had planned to acquire CR Bard (vascular, urological, and oncological diagnosis and intervention products) in a stock swap worth about $3.2bn, including the assumption of debt. However, since Tyco announced it will split into four independent companies, CR Bard and Tyco have mutually agreed to terminate their merger agreement. No break-up fees will be incurred.